At the current PPS, the market cap is only about $9 million, which IMO does not even reflect that there is a potential clinical trial in the pipeline (and another IND). I guess this is an example of a news driven stock, people need to see these 'potential' events become reality first.
If the HemaXellerate clinical trial goes forward, the market cap for Regen BioPharma should be in the $100's of millions, no? This would put the BMSN market cap at around $50 million (as a start), or a PPS around 0.017; a 400%+ gain from current levels.
A question for those with more experience in the clinical trial / investing game: Is there any reason (i.e., scope or scale of the clinical trial and/or the company itself) to believe that HemaXellerate clinical trial aproval would not value Regen BioPharma at $100+ million?
Thanks in advance to those who reply. When I'm bored I like to crunch the numbers, and I keep coming back to the current valuation of BMSN given what we know, and the DD that others have presented.
